Extended treatment trial for rare immune disease halted
NCT ID NCT02859727
Summary
This study aimed to provide long-term treatment with CDZ173 to patients with APDS/PASLI, a rare genetic immune disorder. It followed patients who had previously participated in related studies to monitor the drug's safety and effectiveness over time. The study was terminated and involved 37 participants who continued taking the medication during the research period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pharming Investigative Site
Bethesda, Maryland, 20892, United States
-
Pharming Investigative Site
Minsk, 223053, Belarus
-
Pharming Investigative Site
Prague, CZE, 15006, Czechia
-
Pharming Investigative Site
Dresden, 01307, Germany
-
Pharming Investigative Site
Brescia, BS, 25123, Italy
-
Pharming Investigative Site
Palermo, PA, 90127, Italy
-
Pharming Investigative Site
Rotterdam, 3000 CA, Netherlands
-
Pharming Investigative Site
Moscow, 117198, Russia
Conditions
Explore the condition pages connected to this study.